KLK3 and prostate adenocarcinoma: In the study by Elizabeth M. genega et al. For distinguishing moderate to weak prostate adenocarcinoma and bladder transitional cell carcinoma, they used a large panel of biomarkers including CK7, CK20, HMWK, leuM1, CEA, PSA, Leu7 and B7203.